Once again, our award-winning, independent editorial team provides thought-provoking insights into the business development decisions and financing deals that shaped the world of pharma, biotech and medtech last year. Download Evaluate Vantage’s 2021 in Review now.
Share:
Once again, our award-winning, independent editorial team provides thought-provoking insights into the business development decisions and financing deals that shaped the world of pharma, biotech and medtech last year.
Download Evaluate Vantage’s 2021 in Review now.
Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.
